Clinical implementation of real time motion management for prostate SBRT: A radiation therapist’s perspective
-
Published:2024-09
Issue:
Volume:31
Page:100267
-
ISSN:2405-6324
-
Container-title:Technical Innovations & Patient Support in Radiation Oncology
-
language:en
-
Short-container-title:Technical Innovations & Patient Support in Radiation Oncology
Author:
Mitchell Joanne,
McLaren Duncan B.ORCID,
Burns Pollock Donna,
Wright Joella,
Killean AngusORCID,
Trainer Michael,
Adamson Susan,
McKernan Laura,
Nailon William H.
Funder
Christie Charity
University of Edinburgh
Kingston University
Reference32 articles.
1. Stereotactic body radiotherapy with or without external beam radiation as treatment for organ confined high-risk prostate carcinoma: a six year study;Katz;Radiat Oncol,2014
2. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9-2.2) Gy;Miralbell;Int J Radiat Oncol Biol Phys,2012
3. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial;Widmark;Lancet,2019
4. Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival;Heemsbergen;Radiother Oncol,2014
5. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial;Brand;Lancet Oncol,2019